NEW ORLEANS, Dec. 8, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that subcutaneous injections of low doses of veltuzumab in patients with non-Hodgkin’s lymphoma (NHL) achieved sustained serum levels of pharmacologically active antibody, with objective response rates comparable to those seen with higher intravenous doses.
